The Latest Cardiac and Vascular News
Niagara Falls, NY, Jan. 31, 2022 (GLOBE NEWSWIRE) — Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a nuclear medicine PET imaging company specializing in the field of cardiac Positron Emission Tomography (“PET”) imaging systems and clinical services, is pleased to issue today the following shareholder letter below. The letter […]
Results Presented at the 2022 Annual Meeting for The Society of Thoracic Surgeons ATLANTA, Jan. 31, 2022 /PRNewswire/ — Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the publication of PROACT clinical trial results in The Annals of Thoracic Surgery, the official journal of The Society […]
Former GE Healthcare Imaging and iRhythm leader joins pioneers in clinical decision making and patient care coordination to support continued product innovation and expand global footprint SAN MATEO, Calif.–(BUSINESS WIRE)–RapidAI, the global leader in neurovascular and vascular imaging driving the next evolution of clinical decision making and patient workflow, today […]
PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (Paris:ALCAR): Videoconference in English with Stéphane Piat at 8 pm CET today. To participate, please register by clicking on this link CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic […]
NEW YORK and CARLSBAD, Calif., Jan. 31, 2022 /PRNewswire/ — Pfizer Inc. (NYSE: PFE) and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the discontinuation of the Pfizer-led clinical development program for vupanorsen (PF-07285557), an investigational antisense therapy that was being evaluated for potential indications in cardiovascular (CV) risk reduction and severe hypertriglyceridemia (SHTG). Pfizer made this decision after a thorough […]
– Outcomes of first eight compassionate use cases presented at 46th Annual Winter Meeting of the Vascular and Endovascular Surgery Society – – HAV observed to maintain patency and resist infection in the treatment of critical limb ischemia, infection and vascular trauma – – All patients lacked suitable alternative conduit options – DURHAM, N.C., […]
MILANO, Italy, Jan. 28, 2022 /PRNewswire/ — FONDAZIONE Ricerca e Innovazione Cardiovascolare, Milano, focused on cardiovascular research, reports the first patient enrolment of the TRANSFORM II Randomized Controlled Trial (Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels) setting in motion a crucial trial in the Native Coronary Vessel Treatment domain. TRANSFORM II RCT, determined to […]
– The positive opinion is based on the landmark EMPEROR-Preserved Phase III trial, which showed significant outcomes in patients with heart failure with left ventricular ejection fraction over 40%1 – If approved, Jardiance would be the first and only clinically proven treatment approved for all adults with symptomatic chronic heart failure including […]
InnovHeart and Grand Pharmaceutical Group Enter Into an Exclusive License Agreement to Develop and Commercialize the Saturn TMVR Device in Greater China MILAN, Jan. 27, 2022 /PRNewswire/ — InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of mitral valve disease, announces the closing of its Series […]
IRVINE, Calif., Jan. 26, 2022 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2021. Fourth Quarter Highlights and Outlook 2021 sales grew 19 percent, or 18 percent on an underlying1 basis Q4 sales grew 12 percent to $1.33 billion; underlying 13 percent Q4 TAVR sales grew 12 percent; […]
